Migraine drug developer Biohaven considering potential sale

According to people familiar with the matter, Biohaven Pharmaceutical is examining its options, including a potential sale of the company, after having drawn interest from possible bidders, Bloomberg reported Friday. However, the sources indicated that Biohaven, which develops migraine treatments, is still in the early stages of considering a sale or partnerships, and discussions may not ultimately lead to a transaction. Shares in Biohaven rose as much as 12 percent on the news.

The company, which analysts have identified as a potential target for partnerships or deals, recently secured a priority review voucher to use with the FDA filing for its Zydis orally dissolving tablet formulation of rimegepant in the second quarter of 2019. Late-stage study data released last December showed that the CGRP receptor antagonist significantly increased pain freedom and freedom from the most bothersome symptom at two hours using a single dose, compared with placebo.

Meanwhile, Biohaven is also developing treatments for Alzheimer's disease, inflammation and neurodegeneration. The company initiated patient enrolment last August in a Phase II/III study of the investigational glutamate modulator trigriluzole in the treatment of mild-to-moderate Alzheimer's disease.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.